MDS are mostly seen in the elderly. While the overall incidence is about 2-4 per 100 000 per year, this is 20-30 per 100 000 per year in the population over 70 years. 1 The cliniThirty-five patients with myelodysplastic syndromes (MDS) were treated with BMT between 1986 and 1994.
4,5
Allogeneic BMT offers a potentially curative treatment and in continuous remission with a median follow-up of 20 months (range 15-113) after BMT. Seven patients for younger MDS patients. In a recent review, the probability of 5-year disease-free survival (DFS) following relapsed between 3 and 18 months after BMT and subsequently died. Fourteen transplantation-related deaths BMT in a group of 93 patients was 40%, while the actual DFS varied from 35 to 63% in six smaller studies with occurred. Outcome in patients under and over 40 years old was comparable. The probability of disease-free surshorter follow-up. 6 Median age in these patient groups ranged from 23 to 36 years, and a younger age was found to vival (DFS) at 2 years after BMT was 39% (95% confidence interval (CI), 22-56%). Considering patients with be a favourable prognostic factor. We report a retrospective study of our results of BMT in a group of 35 adults with HLA-identical and MLC-negative sibling donors transplanted for RA (n = 11) or more advanced stages of MDS. This patient group is relatively old as compared to the previously published series.
6
MDS in CR (n = 14), the probabilities of DFS were 73% (95% CI, 47-99%) and 42% (95% CI, 15-69%), respectively. This indicates that BMT with lymphocytedepleted grafts can cure a substantial number of relaPatients and methods tively old patients with MDS, especially when grafts from HLA-identical and MLC-negative siblings are
Between April 1986 and December 1994, 35 patients with MDS were treated with allogeneic BMT. Patient characterused and patients are suffering from RA. Keywords: bone marrow transplantation; myelodysistics and transplantation data are summarized in Table 1 . The median age was 41 years (range 23-60). Thirteen plastic syndromes patients had refractory anaemia (RA) and were transfusiondependent, seven patients had RA with excess of blasts (RAEB), 11 patients had RAEB in transformation (RAEBMyelodysplastic syndromes (MDS) encompass a group of t), and one patient suffered from chronic myelomonocytic clonal haematopoietic disorders. They are characterized by leukaemia (CMMoL), as defined by the French-Americanrefractory cytopenia and dysplastic changes in blood and British (FAB) classification. 7 Three patients had secondary bone marrow, and show a tendency to progress to AML. AML (sAML) which had evolved from MDS. Five out of the total group of 35 patients had developed MDS after previous radiotherapy (for malignant melanoma, n = 1) or severe aplastic anaemia (n = 1). In the others, the MDS was 792 without apparent cause. The median duration of MDS months after transplantation Ϯ2 ϫ s.e. Differences between subgroups were evaluated by the log rank test. P values before BMT was 9 months (range, 4-69). Prior to BMT, 19 patients received remission-induction and consolidation Ͻ0.05 were considered significant. chemotherapy with schedules as used for the treatment of AML. This resulted in CR in 15 patients (four RAEB, nine RAEB-t, one CMMoL, and one sAML), and PR in four Results patients (two RAEB-t and two sAML). None of the 13 patients transplanted for RA were pretreated.
Fourteen out of 35 patients are alive in continuous CR with a median follow-up after BMT of 20 months (range 15-Donors were genotypically HLA-identical and MLCnegative siblings in 32 cases. One patient received a graft 113). Relapse of disease was observed in seven patients, including one patient transplanted for RA, two for RAEB from a two-locus mismatched family member, and two from HLA-identical unrelated donors. Conditioning regiin CR, one for RAEB-t in PR, one for CMMoL in CR, and two transplanted for sAML in PR. These relapses occurred mens consisted of cyclophosphamide (2 ϫ 60 mg/kg i.v.) and TBI (2 ϫ 4, 5-6 Gy) with or without the addition of between 3 and 18 months after BMT (median 6 months). Twenty-one patients have died. Eighteen of them died idarubicin (42 mg/m 2 i.v.) in 31 patients, and other schedules in four patients. All patients received grafts depleted within 6 months (median 2 months) after BMT. Principal causes of death were relapse (n = 4), and transplantationof approximately 98% of T lymphocytes using counterflow centrifugation elutriation, as described before.
8 Immunorelated causes encompassing graft failure (n = 2, including the patient with the two-locus mismatched family donor), prophylaxis post-transplant consisted of cyclosporin A. All patients were cared for in single rooms with filtered air infectious complications (n = 9, including the two patients with matched unrelated donors), acute GVHD (n = 2), and under positive pressure, and all received oral selective gut decontamination, acyclovir for herpes virus prophylaxis, heart failure (n = 1). Three patients died beyond 6 months. All three had undergone retransplantation for relapse. One and cotrimoxazole for Pneumocystis carinii prophylaxis.
Acute GVHD was graded 1 to 4 according to the criteria died of a cerebrovascular accident at 36 months after first BMT, and 10 days after retransplantation which was perdescribed by Glucksberg et al. 9 Chronic GVHD was classified as limited or extensive, as described by Shulman et formed 24 months after relapse of RA. The other two patients were free of disease for 53 and 81 months, respectal. 10 Patients were considered evaluable for acute and chronic GVHD if they survived more than 14 days and ively, after retransplantation for relapsed RAEB. They ultimately relapsed again and died. Remarkably, both late more than 100 days after BMT, respectively.
Statistical analyses were performed using the Kaplanrelapses after second BMT presented primarily as an extramedullary myeloblastic infiltration in soft tissues (stomach Meier product-limit method. Actuarial curves were calculated for relapse and for DFS. 95% confidence intervals and pleural cavity), followed by overt AML at a later stage. Figures 1 and 2 represent probabilities of relapse and DFS, (CI) were calculated as: relapse or DFS estimate at 24
Although there was a tendency towards better outcome in patients with RA (group B), the differences between groups A, B and C were not statistically significant.
According to age two separate groups were analyzed, encompassing patients р40 years and patients Ͼ40 years. With regard to disease and transplantation characteristics, these two groups were largely comparable (Table 1) . On the one hand, the younger group included all three patients without genotypically HLA-identical sibling. On the other hand the older group included less patients with RA (five vs eight, Table 1 ). The probability of DFS for patients р40 years (n = 17) was 33% (95% CI, 9-57%), and for patients Ͼ40 years (n = 18) 44% (95% CI, 21-67%), which was not significantly different (data not shown). relapse-free patients.
Discussion
For patients with MDS and AML evolving from MDS, allogeneic BMT offers the only curative treatment option. Use of BMT, however, is limited to a minority of relatively young patients, especially those with HLA-identical sibling donors. Outcome of BMT in MDS and sAML has been described by several authors, mostly in retrospective analyses of heterogeneous patient groups. 6,11-17 The multiformity of MDS in itself, and the variety of preparative regimens used, obscure comparison and interpretation of reported results. Nevertheless, the actuarial DFS found here for MDS patients following BMT of 39% fits within the range of overall actuarial DFS of 35-56%, as described by others.
6,14-17 Our patient group, with a median age of 41 years, and 26% of the patients being 50-60 years of age, old or younger. Besides a higher median age, use of T cell-depleted marrow grafts effected by counterflow centrifugation elutriation respectively, after BMT. Besides the total group (group A, n = 35), two more homogeneous subgroups were analyzed, is specific for our MDS study group as compared to those published by others. T lymphocyte depletion of the marrow encompassing patients with RA with HLA-identical and MLC-negative sibling donors (group B, n = 11), and graft is performed in order to reduce the incidence and severity of GVHD. GVHD is a serious problem following patients with RAEB, RAEB-t, CMMoL or sAML, transplanted in CR with HLA-identical and MLC-negative siballogeneic BMT, often resulting in death. In the previously reported MDS patient groups, the incidence of fatal GVHD ling donors (group C, n = 14). The probability of relapse ( Figure 1 ) at 2 years after BMT for the total group (A) is was 20-35% in the studies without T cell-depletion 11, 15, 17, 19 and 9-13% in groups, with about 30% of the patients 34% (95% CI, 12-56%), and for the subgroups B and C 11% (95% CI, 0-32%) and 34% (95% CI, 2-66%), respectreceiving T cell-depleted marrow. 12, 13 In comparison to this, the percentage of patients who died of GVHD in the ively. Figure 2 represents continuous DFS following (first) BMT. The median DFS for the total group is 6 months. present study is low (two out of 35, 6%). Lymphocyte depletion implies an increased risk of graft failure and disProbabilities of DFS at 2 years after BMT are 39% (95% CI, 22-56%) for group A, 73% (95% CI, 47-99%) for ease relapse. In two of our 35 patients (6%), graft failure resulting in death occurred. The overall relapse rate of 20%, group B, and 42% (95% CI, 15-69%) for group C. subgroup, as was found by others before. graft failure and two of infectious complications). These 295-304. groups are rather small, but improved outcome of MDS
